RecoveryRx news is spreading... NS Medical Devi
Post# of 7791
(Total Views: 421)
Posted On: 07/04/2019 6:23:08 PM
RecoveryRx news is spreading...
NS Medical Devices
FDA approves BioElectronics’ RecoveryRx device to treat postoperative pain
RegulationApprovals
By rdharma 02 Jul 2019
BioElectronics has secured approval from the US Food and Drug Administration (FDA) for its RecoveryRx medical device to treat postoperative pain.
RecoveryRx will help reduce postoperative pain and exposure to long-term effects of opioid/NSAID therapy, said the company in a statement.
According to the company, less than 50% of patients who undergo surgery report adequate postoperative pain relief.
The approval allows RecoveryRx drug-free therapy to the 15 million Americans who experience postoperative pain from 25 million surgeries per annum.
In addition, RecoveryRx therapy is having a significant market opportunity among the 7 million chronic wound patients with debridement and negative vac therapy treatments.
RecoveryRx uses pulsed electromagnetic therapy to decrease pain and inflammation, helping to accelerate patient recovery and improved comfort.
BioElectronics noted that RecoveryRx has been clinically demonstrated to significantly reduce postoperative pain and the use of narcotic pain medication postoperatively.
The device significantly reduces the required level of pain medications in postoperative surgical recovery, helping to decrease narcotic medication use and side effects and potentially limit the incidence of chronic pain.
https://www.nsmedicaldevices.com/news/fda-bio...ryrx-pain/
NS Medical Devices
FDA approves BioElectronics’ RecoveryRx device to treat postoperative pain
RegulationApprovals
By rdharma 02 Jul 2019
BioElectronics has secured approval from the US Food and Drug Administration (FDA) for its RecoveryRx medical device to treat postoperative pain.
RecoveryRx will help reduce postoperative pain and exposure to long-term effects of opioid/NSAID therapy, said the company in a statement.
According to the company, less than 50% of patients who undergo surgery report adequate postoperative pain relief.
The approval allows RecoveryRx drug-free therapy to the 15 million Americans who experience postoperative pain from 25 million surgeries per annum.
In addition, RecoveryRx therapy is having a significant market opportunity among the 7 million chronic wound patients with debridement and negative vac therapy treatments.
RecoveryRx uses pulsed electromagnetic therapy to decrease pain and inflammation, helping to accelerate patient recovery and improved comfort.
BioElectronics noted that RecoveryRx has been clinically demonstrated to significantly reduce postoperative pain and the use of narcotic pain medication postoperatively.
The device significantly reduces the required level of pain medications in postoperative surgical recovery, helping to decrease narcotic medication use and side effects and potentially limit the incidence of chronic pain.
https://www.nsmedicaldevices.com/news/fda-bio...ryrx-pain/
(2)
(0)BioElectronics Corporation (BIEL) Stock Research Links
Scroll down for more posts ▼